Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice

References

• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
   PubMed Web of Science ®Google Scholar
• Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 2013;19(3):251–258.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992;47(2):109–111.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros. 2010;9(3):217–227.
   PubMed Web of Science ®Google Scholar
• Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol. 2010;300(8):557–562.
   PubMed Web of Science ®Google Scholar
• Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006;36(2):78–91.
   PubMed Web of Science ®Google Scholar
• Fleiszig SM, Evans DJ. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin Exp Optom. 2002;85(5):271–278.
   PubMedGoogle Scholar
• Hobden JA. Pseudomonas aeruginosa proteases and corneal virulence. DNA Cell Biol. 2002;21(5–6):391–396.
   PubMed Web of Science ®Google Scholar
• Hall S, McDermott C, Anoopkumar-Dukie S, et al. Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins (Basel). 2016;8:8.
   Web of Science ®Google Scholar
• Suntres ZE, Omri A, Shek PN. Pseudomonas aeruginosa-induced lung injury: role of oxidative stress. Microb Pathog. 2002;32(1):27–34.
   PubMed Web of Science ®Google Scholar
• Gloyne LS, Grant GD, Perkins AV, et al. Pyocyanin-induced toxicity in A549 respiratory cells is causally linked to oxidative stress. Toxicol In Vitro. 2011;25(7):1353–1358.
   PubMed Web of Science ®Google Scholar
• Jimenez PN, Koch G, Thompson JA, et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 2012;76(1):46–65.
   PubMed Web of Science ®Google Scholar
• Hunt TA,  Peng WT, Loubens I, et al. The Pseudomonas aeruginosa alternative sigma factor PvdS controls exotoxin A expression and is expressed in lung infections associated with cystic fibrosis. Microbiology. 2002;148(Pt 10):3183–3193.
   PubMed Web of Science ®Google Scholar
• Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents. 2001;18(Suppl 1):S3–10.
   PubMed Web of Science ®Google Scholar
• Stellari, F, Bergamini G, Sandri A, et al. In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin. Journal of Translational Medicine. 2015;13:251.
   PubMed Web of Science ®Google Scholar
• Steel HC, Theron AJ, Cockeran R, et al. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012;2012(ID):584262.
   PubMed Web of Science ®Google Scholar
• Wagner T, Soong G, Sokol S, et al. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest. 2005;128(2):912–919.
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. A Randomized Controlled Trial. JAMA.. 2003;290(13):1749–1756.
   Google Scholar
• Pukhalsky AL,  Shmarina GV, Kapranov NI, et al. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004;13(2):111–117.
   PubMed Web of Science ®Google Scholar
• Ordonez CL,  Stulbarg M, Grundland H, et al. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32(1):29–37.
   PubMed Web of Science ®Google Scholar
• Robinson P,  Schechter MS, Sly PD, et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatr Pulmonol. 2012;47(6):551–557.
   PubMed Web of Science ®Google Scholar
• Dogru D, Dalgiç F, Kiper N, et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turk J Pediatr. 2009;51(5):416–423.
   PubMed Web of Science ®Google Scholar
• Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97(7):844–850.
   PubMed Web of Science ®Google Scholar
• Yalcin E, Kiper N, Ozçelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49–55.
   PubMed Web of Science ®Google Scholar
• Tagaya E, Tamaoki J, Kondo M, et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002;122(1):213–218.
   PubMed Web of Science ®Google Scholar
• Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother. 2013;57(6):2694–2704.
   PubMed Web of Science ®Google Scholar
• Elkhatib W, Noreddin A. Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. Microb Drug Resist. 2014;20(6):575–582.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Rosière R, Traina K, et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci. 2013;102(6):1836–1846.
   PubMed Web of Science ®Google Scholar
• Samson C, Tamalet A, Thien HV, et al. Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med. 2016;117:1–6.
   PubMed Web of Science ®Google Scholar
• Travis J, Potempa J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim Biophys Acta. 2000;1477(1–2):35–50.
   PubMed Web of Science ®Google Scholar
• Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31(31):7152–7154.
   PubMed Web of Science ®Google Scholar
• Liesenfeld B. Protease inhibitors prevent microvesication in sulfur mustard wounds on human skin explants. Wound Rep Reg. 2008;16(2):A14–A14.
   Web of Science ®Google Scholar
• Parkinson G, Gaisford S, Ru Q, et al. Characterisation of Ilomastat for prolonged ocular drug release. AAPS Pharm Sci Tech. 2012;13(4):1063–1072.
   PubMed Web of Science ®Google Scholar
• Pemberton PA, Cantwell JS, Kim KM, et al. An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. COPD. 2005;2(3):303–310.
   PubMedGoogle Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27.
   PubMed Web of Science ®Google Scholar
• Rasmussen HS. Batimastat and Marimastat in Cancer. Antiangiogenic Agents in Cancer Therapy. 1999. p. 399–405.
   Google Scholar
• Bergamini G, Stellari F, Sandri A, et al. An IL-8 transiently transgenized mouse model for the in vivo long-term monitoring of inflammatory responses. J Vis Exp. 2017;125:e55499.
   Google Scholar
• Stellari F, Bergamini G, Ruscitti F, et al. In vivo monitoring of lung inflammation in CFTR-deficient mice. J Transl Med. 2016;14:226.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tateda K, Matsumoto T, et al. Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J Antimicrob Chemother. 2002;50(1):59–66.
   PubMed Web of Science ®Google Scholar
• Shusaku S, Yoko M, Katsumi F, et al. Effects of long-term, low-dose macrolide treatment on Pseudomonas aeruginosa PAO1 virulence factors in vitro. Arch Clin Microbiol. 2017;8(4):50.
   Google Scholar
• Bergamini G, Di Silvestre D, Mauri P, et al. MudPIT analysis of released proteins in Pseudomonas aeruginosa laboratory and clinical strains in relation to pro-inflammatory effects. Integr Biol. 2012;4(3):270–279.
   Google Scholar
• Nénan S, Lagente V, Planquois JM, et al. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007;559(1):75–81.
   PubMed Web of Science ®Google Scholar
• Cremonini E, Zonaro E, Donini M, et al. Biogenic selenium nanoparticles: characterization, antimicrobial activity and effects on human dendritic cells and fibroblasts. Microb Biotechnol. 2016;9(6):758–771.
   PubMed Web of Science ®Google Scholar
• Stellari FF, Franceschi V, Capocefalo A, et al. In vivo imaging of transiently transgenized mice with a bovine interleukin 8 (CXCL8) promoter/luciferase reporter construct. PLoS One. 2012;7(6):e39716.
   PubMed Web of Science ®Google Scholar